Physician profile
Sanda Cebular
NPI 1477604536
$3,397.24
in general payments reported to CMS, 2019-2025
14 companies · $748 in 2025
The $748 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $413 · 2021: $300 · 2022: $293 · 2023: $683 · 2024: $687 · 2025: $748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,114 · Education: $4.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,114.03 |
| Education | $4.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $736.86 | 2023-2025 | Fetroja |
| Paratek Pharmaceuticals, INC. | $454.62 | 2021-2025 | Nuzyra |
| Gilead Sciences, INC. | $329.03 | 2019-2025 | |
| Insmed, INC. | $325.52 | 2019-2025 | Arikayce |
| Abbvie INC. | $316.87 | 2021-2025 | Avycaz, Dalvance, Mavyret |
| Melinta Therapeutics, LLC | $287.39 | 2023-2025 | Rezzayo, Kimyrsa, Vabomere |
| Merck Sharp & Dohme LLC | $260.07 | 2019-2024 | Dificid, Zerbaxa, Recarbrio |
| Janssen Biotech, INC. | $251.97 | 2019-2023 | Symtuza |
| Cumberland Pharmaceuticals, INC. | $244.51 | 2021-2025 | Vibativ |
| Viiv Healthcare Company | $58.65 | 2020-2024 | Apretude |
| Allergan, INC. | $58.14 | 2019-2020 | |
| Janssen Products, Lp | $28.99 | 2019 | |
| Aimmune Therapeutics, INC. | $26.56 | 2024 | |
| Janssen Pharmaceuticals, INC | $18.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanda Cebular listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.